The second criminal trial against the former FPÖ vice-chancellor will begin next Tuesday. Entrepreneur Siegfried Stieglitz also has to sit next to him in the dock of the Vienna Regional Court – because of a donation of 10,000 euros to an FPÖ association.
Siegfried Stieglitz is a real estate entrepreneur and clearly wanted to “become something”. Namely management. At Asfinag and another state-owned company. When the Blues were still in government and Heinz Christian Strache was vice chancellor. Chats – surfaced in the inquiry committee of the tiresome Ibiza affair – showed that Stieglitz would have pushed for a commissionership. This would have been agreed upon by ex-FPÖ boss Strache and then Infrastructure Minister Nobert Hofer, also FPÖ. However, the investigations of the Economic and Corruption Prosecutor’s Office (WKStA) against the latter were stopped.
10,000 euros in an account close to the FPÖ
Strache and Stieglitz are now being charged. There is in fact 10,000 euros in the account of the FP association “Austria in Motion”. Paid by Stieglitz – even before he was actually appointed to the Supervisory Board of Asfinag!
Already second trial for bribery
Presumably they wanted to celebrate this “coup” in Dubai, but Strache is said to have declined the invitation for compliance reasons. Strache’s attorney Johann Pauer says: “We already had a travel story in the Prikraf trial, as my client has been legally acquitted.”
But only in this fact, otherwise the former vice chancellor would be sentenced to 15 months in prison – not legally binding – for bribery. In the financing process of private hospitals (Prikraf). There too, donations went to an FP association so that a private clinic could be included in the state billing system…
Source: Krone
I’m an experienced news author and editor based in New York City. I specialize in covering healthcare news stories for Today Times Live, helping to keep readers informed on the latest developments related to the industry. I have a deep understanding of medical topics, including emerging treatments and drugs, the changing laws that regulate healthcare providers, and other matters that affect public health.
